{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:59:19Z","timestamp":1789016359112,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bbmt.2017.11.030","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T15:45:16Z","timestamp":1511970316000},"page":"627-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-9296","authenticated-orcid":false,"given":"Jacopo","family":"Mariotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.11.030_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high-dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0015","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Mart\u00ednez","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0020","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0025","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0035","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0040","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbmt.2008.05.021","article-title":"Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant","volume":"14","author":"Smith","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0045","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0050","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin's lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0055","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2141.2010.08492.x","article-title":"Allogeneic transplantation for Hodgkin's lymphoma","volume":"152","author":"Corradini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0070","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2008.02.014","article-title":"Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation","volume":"14","author":"Tomblyn","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","article-title":"Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma","volume":"49","author":"Raiola","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0085","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0090","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0095","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0110","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0120","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0125","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0130","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0135","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0140","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0145","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V128.22.1165.1165","article-title":"Use of bone marrow or peripheral blood stem cell grafts in non T cell depleted haploidentical transplants using post-transplant cyclophosphamide, an ALWP-EBMT analysis","volume":"128","author":"Ruggeri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0150","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2016.349","article-title":"Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"52","author":"Gauthier","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0155","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/bmt.2016.115","article-title":"Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed\/refractory Hodgkin lymphoma: Spanish multicenter experience","volume":"51","author":"Gayoso","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2007.15.8865","article-title":"Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Rodrigues","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0165","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0170","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.11.030_bib0175","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117308777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117308777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:00Z","timestamp":1761058920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117308777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1083879117308777"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.030","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}